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Background
• 100,000 Americans suffer from sickle cell anemia (SCA).
• A severe hereditary form of anemia in which red blood cells can 
mutate into a sickle shape causing severe pain crises.
• Persistent pain leads to the use of such drugs as duloxetine, 
gabapentin, amitriptyline, and opiates.
• Negatively impacts quality of life.
• Research does suggest that cannabis could have a beneficial 
effect on the management of both chronic pain and acute pain.
• Primary aim: 
– To collect a cohort and perform an initial survey on 
participants that will be used in a larger study.
– The larger study will assess the impact of medicinal 
cannabis available through Pennsylvania’s Department of 
Health-approved dispensaries in Philadelphia on the 
quality of life for individuals with sickle cell anemia.
Methods
• Working with the Lambert Center for the Study of Medicinal 
Cannabis and Hemp. 
• Data using surveys will be collected at baseline regarding the 
participants health-related quality of life, emergency 
department visits, and use of the dispensaries.
Survey
• 20 question survey
• Likert Scale (1 being not sure at all/ less than once a year and 6 
being very sure/ almost every day).
• 3 parts to the survey
Participant Characteristics 
• Participants are being recruited from Jefferson’s Comprehensive Sickle Cell 
Program that provide services for both men and women.
– Patients return on a monthly basis to get refills for their opioid 
prescriptions and we will schedule to meet with them during their 
scheduled appointment time. 
Results 
• Older participants reported:
• Painful episodes occur more often and pain 
impacts daily life more.
• Less likely to use marijuana to manage their pain. 
• Less likely to feel that they can manage their pain 
day to day.
• Males are less likely to visit the emergency room for sickle cell 
pain.
• Participants with higher education levels report lower levels of 
marijuana use and less severe pain. 
Discussion and Limitations
• Dispensaries open in late 2018. 
• Once dispensaries open an additional  survey will be 
administered to gather any changes in participant responses 
regarding quality of life. 
• Aiming to gather 120 participants.
• SCA-specific health-related quality of life survey at 5 time 
points: 
Core Competencies 
• Describe factors affecting the health of a community.
• Research Methodology & Information Literacy Determines 
limitations of the findings. 
• Describes implications of policies, programs and services.
• Describes needs for future development.
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Participant Characteristics 
• Participants were recruited from Jefferson’s Comprehensive 
Sickle Cell Program that provide services for both men and 
women.
• Patients return on a monthly basis to get refills for 
their opioid prescriptions . 
Demographics
Pain related to sickle cell dis ase
Quality of life
Next Steps
One at the 
enrollment 
(baseline) 
3 month time 
point
A third when 
dispensaries 
open




1. To assess changes in Emergency Department (ED) utilization before 
and after the opening of medical marijuana dispensaries in 
Philadelphia County, PA
2. To assess changes in the use of prescription opioids by selected 
individuals with SCA before and after the opening of medical 
marijuana dispensaries.
3. To learn whether selected individuals with SCA will obtain medicinal 
cannabis from PA dispensaries; and if they do, but then discontinue 
medicinal cannabis, the reasons why. 
The results of this pilot study help to establish the demographic 
characteristics of the cohort that will be used in the larger study 
and ensures that the methods used in this pilot will be effective as 
the study progresses. 
Limitations:
• No way to ensure the participants do not use any marijuana 
that is n0t provided by the dispensaries.
• No demographic information collected from participants who 
do not plan to use the dispensaries.
Future Goals
Demographics
Number of Participants Surveyed 35
Number of Participants 12
Gender 8 Females 
Mean Age (years) 35.7 (26-58)
Race
10 African American/ Black
1 Mixed Race
1 Other
Survey Questions Average Likert Scale Results
How often do episodes of severe pain occur? 4.5
How often does pain impact your daily life? 4.75
How often have you visited the ER in the last year because 
of your pain?
3
Have you used marijuana for sickle cell disease pain? 2.3
How sure are you that you can reduce your sickle cell 
disease pain by using methods other than taking extra 
medication? 
2.75
As compared with other people with sickle cell disease, how 
sure are you that you can manage your life from day-to-
day?
3.67
How sure are you that you can keep sickle cell disease pain 
from interfering with your sleep?
2.5
How sure are you that you can do something to cut down 
on most of the pain you have when having a painful 
episode?
3.25
